down arrow

Inozyme Pharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45790W1080
USD
4.00
0.00 (0.00%)

Jul 02

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.725.59
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Mar 2025)

FII

4.82%

Held by 37 FIIs

DII

54.04%

Held by 24 DIIs

Promoter

23.47%

How big is Inozyme Pharma, Inc.?

22-Jun-2025

As of Jun 18, Inozyme Pharma, Inc. has a market capitalization of 257.28 million and reported net sales of 0.00 million with a net profit of -106.71 million over the last four quarters. Shareholder's funds were 57.83 million, and total assets were 123.18 million.

As of Jun 18, Inozyme Pharma, Inc. has a market capitalization of 257.28 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -106.71 million during the same period.<BR><BR>As of Dec 24, the shareholder's funds amounted to 57.83 million, while total assets were reported at 123.18 million.

Read More

What does Inozyme Pharma, Inc. do?

22-Jun-2025

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases related to abnormal mineralization, specifically targeting ENPP1 and ABCC6 deficiencies. As of March 2025, it has a market cap of $257.28 million and reported a net profit loss of $28 million.

Overview: <BR>Inozyme Pharma, Inc. is a rare disease biopharmaceutical company focused on developing therapeutics for diseases of abnormal mineralization, specifically targeting ENPP1 and ABCC6 deficiencies within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -28 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 257.28 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.20 <BR>Return on Equity: -329.63% <BR>Price to Book: 8.09<BR><BR>Contact Details: <BR>Address: 321 SUMMER STREET, SUITE 400, BOSTON MA : 02210 <BR>Tel: 1 857 3304340 <BR>Fax: 1 302 6555049 <BR>Website: http://www.inozyme.com/

Read More

Who are in the management team of Inozyme Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of Inozyme Pharma, Inc. includes Dr. Douglas Treco (Independent Chairman), Mr. Axel Bolte (President and CEO), and several Independent Directors: Ms. Sarah Bhagat, Mr. Reinaldo Diaz, Dr. Martin Edwards, and Dr. Robert Hopfner.

As of March 2022, the management team of Inozyme Pharma, Inc. includes the following individuals:<BR><BR>- Dr. Douglas Treco, who serves as the Independent Chairman of the Board.<BR>- Mr. Axel Bolte, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Sarah Bhagat, who is an Independent Director.<BR>- Mr. Reinaldo Diaz, who is also an Independent Director.<BR>- Dr. Martin Edwards, another Independent Director.<BR>- Dr. Robert Hopfner, who serves as an Independent Director.<BR><BR>This team comprises a mix of leadership roles and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Inozyme Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of June 30, 2025, Inozyme Pharma, Inc. shows a mildly bullish trend with a 44.4% year-to-date return, despite mixed technical signals and underperformance over the past year and three years.

As of 30 June 2025, the technical trend for Inozyme Pharma, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the weekly RSI indicates bearish momentum, and both the KST and Dow Theory show mixed signals with bearish readings on the monthly. In terms of performance, the stock has returned 44.4% year-to-date, significantly outperforming the S&P 500's 12.22% return, but it has underperformed over the 1-year and 3-year periods.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 257 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

96.09%

stock-summary
Debt Equity

-1.20

stock-summary
Return on Equity

-329.63%

stock-summary
Price to Book

8.08

Revenue and Profits:
Net Sales:
(Quarterly Results - Mar 2025)
Net Profit:
-28 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
331.78%
0%
331.78%
6 Months
40.35%
0%
40.35%
1 Year
-9.5%
0%
-9.5%
2 Years
-28.19%
0%
-28.19%
3 Years
-13.61%
0%
-13.61%
4 Years
-76.47%
0%
-76.47%
5 Years
0%
0%
0.0%

Inozyme Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Inozyme Pharma, Inc. technically bullish or bearish?

As of 30 June 2025, the technical trend for Inozyme Pharma, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the weekly RSI indicates bearish momentum, and both the KST and Dow Theory show mixed signals with bearish readings on the monthly. In terms of performance, the stock has returned 44.4% year-to-date, significantly outperforming the S&P 500's 12.22% return, but it has underperformed over the 1-year and 3-year periods....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-29.63%
EBIT to Interest (avg)
-40.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.20
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
92.82%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.10
EV to EBIT
-2.08
EV to EBITDA
-2.10
EV to Capital Employed
-34.64
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-329.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 31 Schemes (17.67%)

Foreign Institutions

Held by 37 Foreign Institutions (4.82%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -20.17% vs -33.91% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.60",
          "val2": "-24.20",
          "chgp": "-5.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "1.30",
          "chgp": "7.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-28.00",
          "val2": "-23.30",
          "chgp": "-20.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -43.26% vs -6.11% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-102.80",
          "val2": "-74.40",
          "chgp": "-38.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.60",
          "val2": "3.30",
          "chgp": "69.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-102.00",
          "val2": "-71.20",
          "chgp": "-43.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - YoYstock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-25.60
-24.20
-5.79%
Interest
1.40
1.30
7.69%
Exceptional Items
-1.90
0.00
Consolidate Net Profit
-28.00
-23.30
-20.17%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -20.17% vs -33.91% in Mar 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-102.80
-74.40
-38.17%
Interest
5.60
3.30
69.70%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-102.00
-71.20
-43.26%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -43.26% vs -6.11% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Inozyme Pharma, Inc. stock-summary
stock-summary
Inozyme Pharma, Inc.
Pharmaceuticals & Biotechnology
Inozyme Pharma, Inc. is a rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
Company Coordinates stock-summary
Company Details
321 SUMMER STREET, SUITE 400 , BOSTON MA : 02210
stock-summary
Tel: 1 857 3304340
stock-summary
http://www.inozyme.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."